Építés alatt – nem éles oldal
Belépés
Fut, nem toboroz3. fázis

Trial of Naltrexone/Bupropion for the Treatment of Methamphetamine Use Disorder

A legfontosabb adatok

Ki végzi
National Institute on Drug Abuse (NIDA)
Hol
Charlottesville, Dallas, Indianapolis, Kansas City, Little Rock, Los Angeles, Memphis, Minneapolis, Pickens, Portland és San Diego (Egyesült Államok)Mind a 11 helyszín megnézése
Azonosító
Állapot
Fut, nem toboroz
Fázis
3. fázis
Résztvevők
360 fő, tervezett
Kezdés
2024. júl. 1.
Várható befejezés
2027. ápr. 30.
A vizsgálat típusa
Beavatkozással járó, 2 csoportAz egyik csoport placebót (hatóanyag nélküli szert) kap, összehasonlításként.
A vizsgált kezelések
  • extended-release naltrexone (XR-NTX)
  • extended release bupropion (BUP-XL) tablets (BUP-XL)
  • iPLB
  • oPLB
A regiszteradat frissítve
2026. július 13.

Ki vehet részt

Életkor
18 év – 65 év
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 29 feltétel megnézéseKevesebb

Ki vehet részt

  • Is 18 to 65 years of age
  • Meets DSM-5 criteria for moderate or severe MUD (4 or more criteria)
  • Is interested in reducing or stopping MA use
  • Is able to speak English sufficiently to understand the study procedures and provide written informed consent to participate in the study
  • Self-reports MA use on 18 or more days in the 30-day period prior to consent using the Timeline Followback (TLFB)
  • Provides at least 2 urine samples positive for MA out of up to 3 tests, which will occur at least 2 days apart within a 10-day period
  • If assigned as female at birth and/or currently has a uterus, is not pregnant, agrees to use acceptable birth control methods, and have periodic urine pregnancy testing done during participation in the study unless documentation of hysterectomy provided
  • Is not physically dependent on opioids and meets subjective and objective measures of being opioid-free prior to naltrexone injection per study medical clinician's determination, including, if clinically required, a negative naloxone challenge
  • Is willing to comply with all study procedures and medication instructions
  • Agrees to use a smartphone app (downloaded for free to own device or on a study provided smartphone device) to take daily videos of medication dosing

Ki nem vehet részt

  • Has been in a prior study of pharmacological or behavioral treatment for MUD within 6 months of study consent
  • Has taken an investigational drug in another study within 30 days of study consent
  • Is receiving ongoing treatment with tricyclic antidepressants, xanthines (i.e., theophylline and aminophylline), systemic corticosteroids, nelfinavir, efavirenz, chlorpromazine, MAOIs, central nervous system stimulants (e.g., Adderall, Ritalin, etc.), or any medication that, in the judgment of the study medical clinician, could interact adversely with study medications
  • Requires treatment with opioid-containing medications (e.g., opioid analgesics) during the study period
  • Has a surgery planned or scheduled during the study period
  • Has an acute medical or psychiatric disorder that would, in the judgment of the study medical clinician, make participation difficult or unsafe
  • Has a history of epilepsy, seizure disorder, or head trauma with neurological sequelae (e.g., loss of consciousness that required hospitalization); current anorexia nervosa or bulimia; or any other conditions that increase seizure risk in the opinion of the study medical clinician
  • Has Stage 2 hypertension as determined by the study medical clinician (e.g., greater than or equal to 160/100 in 2 out of 3 readings during screening)
  • Has a known allergy or sensitivity to bupropion, naloxone, naltrexone, PLG (polyactideco-glycolide), carboxymethylcellulose or any other component of the XR-NTX diluents
  • Is concurrently enrolled in formal behavioral or pharmacological Substance Use Disorder (SUD) treatment services
  • Has evidence of second or third degree heart block, atrial fibrillation, atrial flutter, prolongation of the QTc, or any other finding on the screening ECG that, in the opinion of the study medical clinician, would preclude safe participation in the study
  • Has any elevated bilirubin test value per laboratory criteria OR any other liver function test (LFT) value > 5 times the upper limit of normal per laboratory criteria
  • Has a platelet count <100 x 10exp3/microliter
  • Has suicidal or homicidal ideation that requires immediate attention
  • Has a body habitus that precludes gluteal intramuscular injection of XR-NTX in accordance with the administration equipment (needle) and procedures
  • Has been prescribed and taken naltrexone or bupropion within 30 days of study consent
  • Has a current pattern of alcohol, benzodiazepine, or other sedative hypnotic use which would preclude safe participation in the study as determined by the study medical clinician
  • Is currently in jail, prison or any inpatient overnight facility as required by court of law or have pending legal action or other situation (e.g., unstable living arrangements) that could prevent participation in the study or in any study activities
  • If assigned as female at birth and/or currently has a uterus, is currently pregnant, breastfeeding, or planning on conception

Helyszínek itt: Egyesült Államok

  • University of VirginiaCharlottesville, Egyesült Államok
  • University of Texas Southwestern Medical CenterDallas, Egyesült Államok
  • Indiana UniversityIndianapolis, Egyesült Államok
  • University of Kansas Medical CenterKansas City, Egyesült Államok
  • University of Arkansas for Medical SciencesLittle Rock, Egyesült Államok
  • University of California, Los AngelesLos Angeles, Egyesült Államok
  • University of TennesseeMemphis, Egyesült Államok
  • University of MinnesotaMinneapolis, Egyesült Államok
  • MUSC/BHSPickens, Egyesült Államok
  • CODAPortland, Egyesült Államok
  • University of California At San DiegoSan Diego, Egyesült Államok

A vizsgálatról

Mit akar kideríteni a vizsgálat

The primary objective of this study is to evaluate the efficacy of extended release naltrexone plus bupropion XL (XR-NTX/BUP-XL) compared to matched injectable and oral placebo (iPLB/oPLB) in reducing methamphetamine (MA) use in individuals with moderate or severe methamphetamine use disorder (MUD) seeking to stop or reduce MA use.

A vizsgálat 2 csoportja

  • XR-NTX/BUP-XLA vizsgált kezelés

    Participants randomized to the (XR-NTX/BUP-XL) arm will receive 450 mg of once-daily oral extended-release bupropion tablets and once every three weeks (Weeks 1, 4, 7, and 10) injections of extended-release naltrexone (Vivitrol®)

    Kezelés: extended-release naltrexone (XR-NTX) és extended release bupropion (BUP-XL) tablets (BUP-XL)

  • PLB/PLBPlacebo, összehasonlításként

    Participants randomized to the PLB arm will receive once-daily placebo tablets and once every three weeks (Weeks 1, 4, 7, and 10) placebo injections.

    Kezelés: iPLB és oPLB

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
Randomized, Placebo-Controlled, Multi-Site Trial of Extended-Release Naltrexone Injection/Bupropion XL Tablets in the Treatment of Methamphetamine Use Disorder
A regiszteradat frissítve
2026. július 13.